<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056741</url>
  </required_header>
  <id_info>
    <org_study_id>ProVia-01</org_study_id>
    <nct_id>NCT04056741</nct_id>
  </id_info>
  <brief_title>Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot Study</brief_title>
  <official_title>A Supraglottic Instillation Device for Administration of Surfactant in Neonates- A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ONY</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ONY</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to explore and determine feasibility and safety of the administration of
      surfactant through a new supraglottic device in patients from 500 to 5000 grams with RDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surfactant therapy can be life-saving for newborn infants with respiratory distress due to
      surfactant insufficiency, also known as respiratory distress syndrome (RDS). All commercially
      available surfactants for clinical use are approved for administration through an
      endotracheal tube. Placement of an endotracheal tube, a procedure called intubation, is
      stressful for the infant and associated with significant adverse effects. The proposed
      supraglottic instillation device allows infants to benefit from surfactant therapy while
      avoiding the negative effects of intubation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pilot Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Instillation failures</measure>
    <time_frame>First 10 minutes after surfactant instillation.</time_frame>
    <description>Instillation failure is defined as a lack of clinical response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>First 3 days of life</time_frame>
    <description>&quot;Treatment failure&quot; defined as requiring intubation and liquid surfactant instillation with or without mechanical ventilation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>3 days</time_frame>
    <description>Duration of oxygen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>3 days</time_frame>
    <description>duration of non-invasive respiratory therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>3 days</time_frame>
    <description>number of rescue surfactant doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>3 days</time_frame>
    <description>incidence of pulmonary air leak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>3 days</time_frame>
    <description>pulmonary hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>defined as need for oxygen at 36 weeks post menstrual age</time_frame>
    <description>chronic lung disease</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>RDS of Prematurity</condition>
  <condition>Surfactant Protein B Deficiency</condition>
  <condition>Chronic Lung Disease</condition>
  <arm_group>
    <arm_group_label>Surfactant administered via supraglottic administration device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will have Calfactant at 3ml/kg administered via the supraglottic administration device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>surfactant airway device</intervention_name>
    <description>Infants who meet eligibility criteria and have a signed consent form by their parent or guardian will be enrolled in the study. Once enrolled, the surfactant airway device placement and surfactant administration will occur as detailed in the protocol. The infant will be monitored. If the infant meets instillation failure criteria, the procedure will be repeated shortly after the initial procedure. A maximum of two (2) doses will be given during the initial procedure. If the infant meets re-dosing criteria, (s)he may receive up to two (2) additional doses through the surfactant airway device (initial procedure with 1-2 doses and up to two additional doses). If at any time the infant reaches treatment failure criteria, the infant would be intubated and receive a site-specific surfactant through an endotracheal tube. Study outcome data will be followed until discharge from the NICU.</description>
    <arm_group_label>Surfactant administered via supraglottic administration device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age at the time of enrollment ≥ 24 0/7 weeks

          -  Weight at the time of enrollment 500- 5000 grams

          -  Age ≤ 24 hours old

          -  Require non-invasive respiratory support (i.e. continuous positive airway pressure,
             high flow nasal cannula or non-invasive ventilation)

          -  Require FiO2 ≤ 40%

          -  Clinical diagnosis of RDS

        Exclusion Criteria:

          -  Prior surfactant administration

          -  Prior mechanical ventilation

          -  Major congenital anomaly

          -  Abnormality of the airway

          -  Respiratory distress secondary to an etiology other than RDS (suspected pulmonary
             hypoplasia, pneumothorax, meconium aspiration syndrome, pneumonia, septic or
             hypovolemia shock, hypoxic ischemic encephalopathy)

          -  Apgar score &lt; 5 at 5 minutes of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Weeks</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kari Roberts, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kari Roberts, MD - University of Minnesota, Minneapolis, MN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corey J Commaroto, AAS,RRT</last_name>
    <phone>7164283124</phone>
    <email>ccommaroto@onybiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Swartz, PhD</last_name>
    <phone>7164283132</phone>
    <email>dswartz@onybiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sharp Mary Birch Hospital for Women &amp; Newborns</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alona Diem</last_name>
      <phone>858-939-4301</phone>
      <email>Alona.Diem@sharp.com]</email>
    </contact>
    <investigator>
      <last_name>Anup Katheria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Denise Martinez</last_name>
      <email>dmarti95@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Prem Fort, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sisters of Charity Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>George Albert, MD</last_name>
      <phone>716-862-1000</phone>
    </contact>
    <investigator>
      <last_name>George Albert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jackson-Madison County General Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sharon Wadley, BSN</last_name>
      <email>sharon.wadley@wth.org</email>
    </contact>
    <investigator>
      <last_name>Scott Guthrie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neonatal RDS</keyword>
  <keyword>RDS</keyword>
  <keyword>Surfactant Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

